Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.本發明提供ROR1結合分子,包括抗ROR1抗體,包括抗體片段,諸如可變重鏈(VH)區、單鏈片段;及包括該等抗體之嵌合受體,諸如嵌合抗原受體(CARs)。在一些實施例中,抗體特異性結合於ROR1。在該等抗體中有人類抗體,包括與參考抗體(諸如非人類參考抗體)競爭結合於ROR1者。亦提供表現嵌合受體的經基因工程改造之細胞,及該等結合分子及細胞用於授受(adoptive)細胞療法的用途。
